Federal News

Displaying results 1-10 (of 81)
 |<  < 1 2 3 4 5 6 7 8 9  >  >| 

Federal Rebate Rule Withdrawn by White House

On July 11th, the White House announced that it was withdrawing its proposal to reformulate the way drug rebates work in federal programs.

READ MORE

CMS Issues Final Rule Affecting Patient Access and Prescription Drug Affordability

The Centers for Medicare and Medicaid (CMS) published its “Medicare Advantage and Part D Drug Pricing Final Rule” in May which seeks to increase drug pricing transparency, lower prescription drug costs, and improve patient medication adherence.

READ MORE

CSRO President Testifies Before Congress

Last week, the House Energy and Commerce Subcommittee on Health held a hearing entitled: “Improving Drug Pricing Transparency and Lowering Prices for American Consumers.” CSRO President, Dr. Madelaine Feldman, was invited to represent the Alliance for Specialty Medicine and deliver testimony at the hearing.

READ MORE

FDA Releases Final Guidance on Interchangeable Biosimilars

Last week, the FDA released its long anticipated final guidance for industry on “Considerations in Demonstrating Interchangeability with a Reference Product.”

READ MORE

CSRO offers Federal Policy Virtual “Town Hall” to Rheumatology Community

The gridlock immobilizing Congress has slowed the progress of health care legislation significantly, but it has not stopped key Federal agencies from proposing and implementing policies that have a far reaching impact on the practice of rheumatology.

READ MORE

CSRO Comments on Proposed Rule to Eliminate Safe Harbor Protections for Prescription Drug Rebates

The Coalition of State Rheumatology Organizations (CSRO) recently submitted comments on the Department of Health and Human Services (HHS) proposed rule amending the Federal anti-kickback statute.

READ MORE

CSRO’s Dr. Robert Levin Discusses Drug Pricing in the U.S.

CSRO Board Member, Robert Levin, participated in the Healthcare Policy podcast on February 18 to discuss federal prescription drug pricing reform. In his capacity as a practicing physician, and president the Alliance for Transparent and Affordable Prescriptions, Dr. Levin provided expert testimony on drug pricing reform proposals and how the drug supply chain works.

READ MORE

PBMs and New Approaches to Drug Pricing in 2019

Without a doubt, lowering list-prices for prescription drugs was a national focus in 2018. Coupled with numerous advocacy organizations bringing increased awareness to Pharmacy Benefit Managers’ (PBMs) unfair practices, and their effect on drug prices, several reforms have sparked across the U.S. and are expected to increase in intensity in 2019.

READ MORE

CSRO Submits IPI Comments

Prior to commenting on the proposed International Pricing Index Model (IPI) for Part B drugs, CSRO leadership met with Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma to convey rheumatology's perspective.

READ MORE

Express Scripts Announces New Formulary Design Option

This week, Express Scripts announced that it would provide clients with the ability to opt for its new National Preferred Flex Formulary Design. As opposed to favoring drugs that garner the most rebate dollars, the new benefit design intends to favor drugs that have lower list prices to begin with.

READ MORE

Displaying results 1-10 (of 81)
 |<  < 1 2 3 4 5 6 7 8 9  >  >|